Results 91 to 100 of about 25,074 (200)

Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina. [PDF]

Cancers (Basel), 2022
Pennella CL, Cassina TM, Rossi JG, Baialardo EM, Rubio P, Deu MA, Peruzzo L, Guitter MR, Sanchez de La Rosa CG, Alfaro EM, Felice MS.   +10 more
europepmc   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Histamine and Serotonin Levels in Bone Marrow Stem Cells Niche as Potential Biomarkers of Systemic Mastocytosis and Myeloproliferative Disorders. [PDF]

Stem Cell Rev Rep, 2023
Janus T, Korbal U, Żukowski M, Lewosiuk A, Koper K, Żukowska A, Brzeźniakiewicz-Janus K.   +6 more
europepmc   +1 more source

A Rare Case of Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in an Elderly Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Chronic Lymphocytic Leukemia (CLL) and Chronic Myeloid Leukemia (CML) are two distinct hematological malignancies with different pathophysiologies and clinical courses. While each is relatively common in the elderly population, their simultaneous occurrence in a single patient is exceptionally rare and poses diagnostic and therapeutic ...
Mostafa Kamandi, Mohammad Mahdi Alvandi Fard   +1 more
wiley   +1 more source

Myelodysplastic/myeloproliferative disorders

Haematologica, 2008
Luca Malcovati, Mario Cazzola
doaj   +1 more source

Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. [PDF]

J Clin Med, 2021
Kuznetsova PI, Raskurazhev AA, Konovalov RN, Krotenkova MV, Chechetkin AO, Lagoda OV, Melikhyan AL, Tanashyan MM.   +7 more
europepmc   +1 more source

Extensive Cerebral Venous Sinus Thrombosis With Obstructive Hydrocephalus in a Young Female With Underlying Essential Thrombocythemia: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Persistent symptoms suggestive of idiopathic intracranial hypertension despite standard therapy should prompt urgent neuroimaging to exclude cerebral venous sinus thrombosis. When CVST is confirmed without an obvious provoking factor, evaluation for underlying myeloproliferative neoplasms, including JAK2‐positive essential thrombocythemia, is ...
Sarah Nafea, Tasmia Farooq, Md Abu Taher, Andrea Barros, Kyaw Naing Soe, Fawad Ali, Koshy Thomas   +6 more
wiley   +1 more source

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation. Mutations in TET2 are common drivers of leukemia. Preclinical studies suggest that VitC may delay leukemia progression. This study aimed to evaluate the biological activity, safety, and clinical impact of oral VitC in patients ...
Stine Ulrik Mikkelsen, Ali Al‐Mousawi, Amalie Bach Puglisi, Anders Pommer Vallentin, Astrid Østergaard Mortensen, Zachary Madaj, Toshinori Hinoue, Heidi Naomi Ottesen, Jakob Schmidt Jespersen, Linn Gillberg, Morten Tulstrup, Niels Richard Hansen, Jakob Werner Hansen, Mette Klarskov Andersen, Stacey Lyn Thomas, Christine Isaguirre, Ryan Sheldon, Marie Adams, Ryan Burgos, Stephen Baylin, Bo Kok Mortensen, Casey Lee O’Connell, Marianne Tang Severinsen, Peter William Laird, Jens Lykkesfeldt, Peter Jones, Kirsten Grønbæk   +26 more
wiley   +1 more source

Insights Into the Role of Platelet Factor 4 in Neurodegenerative Diseases

CNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.
This review summarizes potential functions of platelet factor 4 (PF4) in neurodegenerative diseases (NDs) and discusses its promise as both a biomarker and a therapeutic target. Further elucidation of PF4 signaling pathways may provide new insights into disease mechanisms and uncover novel opportunities for targeted interventions in NDs.
Qi Tian, Yanji Tong, Fang Yu, Xiaoming Hu   +3 more
wiley   +1 more source

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders

Haematologica, 2004
BACKGROUND AND OBJECTIVES: Although anagrelide is widely used in the treatment of thrombocythemia in myeloproliferative diseases, there is currently limited information on the efficacy and toxicity of its long-term use.
G Birgegard, M Bjorkholm, J Kutti, G Larfars, E Lofvenberg, B Markevarn, M Merup, J Palmblad, N Mauritzson, J Westin, J Samuelsson   +10 more
doaj